SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 272 filers reported holding SAGE THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 0.97 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $971,000 | -81.7% | 5,307 | -84.1% | 1.05% | -80.9% |
| Q1 2019 | $5,302,000 | +1511.6% | 33,330 | +870.6% | 5.51% | +1323.3% |
| Q4 2018 | $329,000 | -72.3% | 3,434 | -59.2% | 0.39% | -59.0% |
| Q3 2018 | $1,187,000 | -78.4% | 8,408 | -76.1% | 0.94% | -78.3% |
| Q2 2018 | $5,505,000 | +59.2% | 35,174 | +63.8% | 4.36% | +67.2% |
| Q1 2018 | $3,459,000 | +226.3% | 21,477 | +234.0% | 2.61% | +270.2% |
| Q4 2017 | $1,060,000 | – | 6,431 | – | 0.70% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
| Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
| Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
| BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
| TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
| Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
| RA Capital Management | 350,933 | $49,569,000 | 2.65% |
| Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
| OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |